PECAM1 and neoplasm: Tumor-associated angiogenesis also showed a significant reduction among CNTNAP4 KO implants compared to control (Fig. 2g, h, 81.5% reduction in CD31 labeling), in line with prior reports of the angiogenic effects of CNTNAP4 signaling11.